Showing 1426 results
-
Press release /Novartis agrees to take actions aimed at meeting US Administration priorities for drug pricingAdditional Novartis medicines will be made available through direct-to-patient platforms in 2026Company…
-
Press release /Novartis exercises an option to in-license ECF843, a recombinant form of human lubricin from Lubris LLC, for ophthalmic indications worldwide (outside Europe) Dry eye is an area with high unmet…
-
Press release /Sandoz proposed biosimilar adalimumab (GP2017) shown to have equivalent efficacy and a similar safety profile as reference medicine, Humira®*Comprehensive development program show potential of GP2017…
-
Press release /Positive opinion is based on comprehensive data confirming that Sandoz biosimilar pegfilgrastim matches the reference medicine in terms of safety, efficacy and qualitySandoz seeks approval in the…
-
Press release /US Food and Drug Administration (FDA) grants approval of the AcrySof® IQ ReSTOR® +2.5 Diopter (D) Intraocular Lens (IOL) for sale in the US Expands Alcon's IOL portfolio for the …
-
Press release /CHICAGO, Jan. 16, 2018 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS) today announced that it intends to offer and sell, subject to market conditions, up to $400 million of shares of its…
-
Press release /Approval based on COMBI-AD study demonstrating greater than 50% reduction in risk of disease recurrence or death in stage III melanoma patients More than 50% of stage III melanoma…
-
Press release /Progression-free survival (PFS) in ALKi-naïve patients is consistent with results previously reported from Phase I ASCEND-1 study Phase II study also showed overall response rate of 63.3% in…
-
Story /Neurological diseases develop out of sight. Novartis neuroscientists are bringing them into the light, using human brain cells grown in the lab.
-
Story /